Skip Ribbon Commands
Skip to main content
Navigate Up
Search
Test Code
Search
Laboratory Section
Test Category
Browse By Test Name
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Striational (Striated Muscle) Antibodies (STR)
Test Code: STRIASO
Synonyms/Keywords
Anti-Skeletal Muscle Antibodies, Anti-Striated Antibody, Muscle (Skeletal) Antibodies, Myasthenia Gravis Antibodies, Myoid Antibody, Skeletal Muscle Antibodies, Striational (Striated Muscle) Antibodies
Useful For
As a serological aid in the diagnosis of thymoma, especially in patients with onset of myasthenia gravis (MG) younger than 45 years
 
As a screening test for MG in older patients, especially when tests for muscle acetylcholine receptor (AChR) antibodies are negative
 
Serial measurements are useful in monitoring the efficacy of immunosuppressant treatment in patients with MG
 
Serial measurements are useful after treatment of thymoma
 
Serial measurements in recipients of D-penicillamine or bone marrow allografts may be useful in monitoring autoimmune complications and graft-versus-host disease, respectively
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum Red Top Tube (RTT)​ Serum Separator Tube (SST)​ 1.5 mL​ 1.0 mL​
Specimen Stability Information
Specimen Type Temperature Time
Serum​ ​ ​ Refrigerated (preferred)​ 28 days​
Ambient ​ 72 hours​
Frozen​ ​ ​28 days
Rejection Criteria
Gross hemolysis
​Gross lipemia
​Gross icterus
Interference
​A negative result does not exclude the presence of thymoma (20% are negative).
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories
Monday through Friday
3 days
Enzyme Immunoassay (EIA)​
Reference Lab
Reference Range Information
<1:120
Interpretation
Striational antibodies occur in approximately:
-14% of patients with thymoma without clinical evidence of myasthenia gravis (MG)
-30% of patients with acquired (autoimmune) MG
-74% of patients with thymoma in association with MG
-25% of rheumatoid arthritis (RA) patients treated with D-penicillamine, 4% in untreated RA patients
-5% of patients with Lambert-Eaton myasthenic syndrome (LES) and/or small-cell lung carcinoma (SCLC) (MGL1 / Myasthenia Gravis [MG]/Lambert-Eaton Syndrome [LES] Evaluation and PAVAL / Paraneoplastic Autoantibody Evaluation, Serum)
-In some bone marrow recipients with graft-versus-host disease
 
The incidence in healthy subjects is under 1%.
 
A rising titer after removal of thymoma may be indicative of tumor recurrence.
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​83520
Synonyms/Keywords
Anti-Skeletal Muscle Antibodies, Anti-Striated Antibody, Muscle (Skeletal) Antibodies, Myasthenia Gravis Antibodies, Myoid Antibody, Skeletal Muscle Antibodies, Striational (Striated Muscle) Antibodies
Ordering Applications
Ordering Application Description
Centricity ​Anti-Striational Ab
​Cerner ​Striated Muscle Antibody IgG (8746)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum Red Top Tube (RTT)​ Serum Separator Tube (SST)​ 1.5 mL​ 1.0 mL​
Specimen Stability Information
Specimen Type Temperature Time
Serum​ ​ ​ Refrigerated (preferred)​ 28 days​
Ambient ​ 72 hours​
Frozen​ ​ ​28 days
Rejection Criteria
Gross hemolysis
​Gross lipemia
​Gross icterus
Interference
​A negative result does not exclude the presence of thymoma (20% are negative).
Useful For
As a serological aid in the diagnosis of thymoma, especially in patients with onset of myasthenia gravis (MG) younger than 45 years
 
As a screening test for MG in older patients, especially when tests for muscle acetylcholine receptor (AChR) antibodies are negative
 
Serial measurements are useful in monitoring the efficacy of immunosuppressant treatment in patients with MG
 
Serial measurements are useful after treatment of thymoma
 
Serial measurements in recipients of D-penicillamine or bone marrow allografts may be useful in monitoring autoimmune complications and graft-versus-host disease, respectively
Reference Range Information
<1:120
Interpretation
Striational antibodies occur in approximately:
-14% of patients with thymoma without clinical evidence of myasthenia gravis (MG)
-30% of patients with acquired (autoimmune) MG
-74% of patients with thymoma in association with MG
-25% of rheumatoid arthritis (RA) patients treated with D-penicillamine, 4% in untreated RA patients
-5% of patients with Lambert-Eaton myasthenic syndrome (LES) and/or small-cell lung carcinoma (SCLC) (MGL1 / Myasthenia Gravis [MG]/Lambert-Eaton Syndrome [LES] Evaluation and PAVAL / Paraneoplastic Autoantibody Evaluation, Serum)
-In some bone marrow recipients with graft-versus-host disease
 
The incidence in healthy subjects is under 1%.
 
A rising titer after removal of thymoma may be indicative of tumor recurrence.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
Mayo Medical Laboratories
Monday through Friday
3 days
Enzyme Immunoassay (EIA)​
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​83520
For most current information refer to the Marshfield Laboratory online reference manual.